ANGLE plc (AGL) - Total Liabilities

Latest as of June 2025: GBX6.39 Million GBX ≈ $777.48 USD

Based on the latest financial reports, ANGLE plc (AGL) has total liabilities worth GBX6.39 Million GBX (≈ $777.48 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ANGLE plc - Total Liabilities Trend (2001–2024)

This chart illustrates how ANGLE plc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of ANGLE plc to evaluate short-term liquidity relative to the company's equity base.

ANGLE plc Competitors by Total Liabilities

The table below lists competitors of ANGLE plc ranked by their total liabilities.

Company Country Total Liabilities
ADVANCED INF SERV(ADVANC)
STU:NVAA
Belgium €312.99 Billion
Tern Plc
LSE:TERN
UK GBX655.00K
Tanfield Group PLC
LSE:TAN
UK GBX582.00K
Fiske PLC
LSE:FKE
UK GBX4.34 Million
Sotherly Hotels Inc Series B Pref
NASDAQ:SOHOB
USA $379.65 Million
Tower Resources plc
LSE:TRP
UK GBX4.26 Million
Georgina Energy PLC
LSE:GEX
UK GBX3.13 Million

Liability Composition Analysis (2001–2024)

This chart breaks down ANGLE plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AGL market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.13 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.55 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.35 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ANGLE plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ANGLE plc (2001–2024)

The table below shows the annual total liabilities of ANGLE plc from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 GBX7.02 Million
≈ $853.77
-14.88%
2023-12-31 GBX8.24 Million
≈ $1.00K
-15.92%
2022-12-31 GBX9.80 Million
≈ $1.19K
+40.37%
2021-12-31 GBX6.99 Million
≈ $849.87
+48.46%
2020-12-31 GBX4.71 Million
≈ $572.46
+18.28%
2019-12-31 GBX3.98 Million
≈ $484.01
+7.98%
2019-04-30 GBX3.68 Million
≈ $448.24
+53.63%
2018-04-30 GBX2.40 Million
≈ $291.77
+13.54%
2017-04-30 GBX2.11 Million
≈ $256.97
+40.43%
2016-04-30 GBX1.50 Million
≈ $182.99
+32.98%
2015-04-30 GBX1.13 Million
≈ $137.61
+75.35%
2014-04-30 GBX645.00K
≈ $78.48
-12.41%
2013-04-30 GBX736.42K
≈ $89.60
-5.47%
2012-04-30 GBX779.00K
≈ $94.78
+8.04%
2011-04-30 GBX721.00K
≈ $87.72
-42.18%
2010-04-30 GBX1.25 Million
≈ $151.72
-23.45%
2009-04-30 GBX1.63 Million
≈ $198.20
-16.85%
2008-04-30 GBX1.96 Million
≈ $238.35
-4.21%
2007-04-30 GBX2.04 Million
≈ $248.82
+24.77%
2006-04-30 GBX1.64 Million
≈ $199.42
0.00%
2005-04-30 GBX1.64 Million
≈ $199.42
+53.18%
2004-04-30 GBX1.07 Million
≈ $130.19
+112.72%
2003-04-30 GBX503.00K
≈ $61.20
+32.72%
2002-04-30 GBX379.00K
≈ $46.11
+6.16%
2001-04-30 GBX357.00K
≈ $43.44
--

About ANGLE plc

LSE:AGL UK Diagnostics & Research
Market Cap
$94.18K
GBX774.07 Million GBX
Market Cap Rank
#31304 Global
#1130 in UK
Share Price
GBX2.40
Change (1 day)
-9.43%
52-Week Range
GBX1.75 - GBX7.50
All Time High
GBX156.00
About

ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more